公开(公告)号：WO2012027247A3

公开(公告)日：2012-05-24

申请号：PCT/US2011048565

申请日：2011-08-22

Applicant: VERTEX PHARMA ,  ALARGOVA ROSSITZA GUEORGUIEVA ,  DUNBAR CRAIG ANTONY ,  KADIYALA IRINA NIKOLAEVNA

Inventor： ALARGOVA ROSSITZA GUEORGUIEVA ,  DUNBAR CRAIG ANTONY ,  KADIYALA IRINA NIKOLAEVNA

IPC: A61K9/20 ,  A61K31/404

CPC classification number: A61K31/404 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2077

Abstract: A pharmaceutical composition comprising Compound 1, (R)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2- methylpropan-2-yl)-lH-indol-5-yl)cyclopropanecarboxamide, and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering the pharmaceutical composition of Compound 1 are also disclosed.

Abstract translation: 包含化合物1，（R）-1-（2,2-二氟苯并[d] [1,3]间二氧杂环戊烯-5-基）-N-（1-（2,3-二羟丙基）-6-氟 -2-（1-羟基-2-甲基丙-2-基）-1H-吲哚-5-基）环丙烷甲酰胺和至少一种赋形剂，其选自填料，稀释剂，崩解剂，表面活性剂，助流剂和 润滑剂，该组合物适合于有需要的患者口服给药以治疗CFTR介导的疾病例如囊性纤维化。 用于治疗有需要的患者的方法包括给药化合物1的药物组合物也被公开。

公开(公告)号：WO2011127241A3

公开(公告)日：2012-02-02

申请号：PCT/US2011031519

申请日：2011-04-07

Applicant: VERTEX PHARMA ,  VERWIJS MARINUS JACOBUS ,  ALARGOVA ROSSITZA GUEORGUIEVA ,  KAUSHIK RITU ROHIT ,  KADIYALA IRINA NIKOLAEVNA ,  YOUNG CHRISTOPHER RYAN

Inventor： VERWIJS MARINUS JACOBUS ,  ALARGOVA ROSSITZA GUEORGUIEVA ,  KAUSHIK RITU ROHIT ,  KADIYALA IRINA NIKOLAEVNA ,  YOUNG CHRISTOPHER RYAN

IPC: A61K9/16 ,  A61K9/20 ,  A61K9/28 ,  C07D213/75 ,  C07D405/12 ,  C07D405/14

CPC classification number: A61K31/443 ,  A61K9/0053 ,  A61K9/1682 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2095 ,  A61K31/47

Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2- difluorobenzo [d] [ 1,3 ] dioxol-5 -y1) cyclopropanecarboxamido)-3 -methylpyridin-2-y1)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.

Abstract translation: 包含化合物1（3-（6-（1-（2,2-二氟苯并[d] [1,3]二氧杂环戊烯-5-基）环丙烷甲酰氨基）-3-甲基吡啶-2-基）苯甲酸的药物组合物 和至少一种选自：填料，稀释剂，崩解剂，表面活性剂，粘合剂，助流剂和润滑剂的赋形剂，所述组合物适合于有需要的患者口服给药以治疗CFTR介导的疾病，例如 作为囊性纤维化。 用于治疗有需要的患者的方法包括向患者施用化合物1的口服药物制剂。

公开(公告)号：EP3250562A4

公开(公告)日：2018-07-11

申请号：EP16744240

申请日：2016-01-29

Applicant: BIOMED VALLEY DISCOVERIES INC ,  VERTEX PHARMA

Inventor： DECRESCENZO GARY ,  WELSCH DEAN ,  VLAHOVA PETINKA I ,  BOERRIGTER STEPHAN X M ,  ARONOV ALEXANDER ,  KESHAVARZ-SHOKRI ALI ,  SCANGAS ALEXANDER N ,  STAVROPOULOS KATHY ,  LITTLER BENJAMIN ,  KADIYALA IRINA NIKOLAEVNA ,  ALARGOVA ROSSITZA GUEORGUIEVA

IPC: C07D401/04 ,  A61K31/4439 ,  A61K45/06 ,  A61P35/00

CPC classification number: C07D401/04 ,  A61K31/4439 ,  A61K45/06 ,  A61P35/00

Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.

公开(公告)号：AR120065A2

公开(公告)日：2022-02-02

申请号：ARP200101884

申请日：2020-07-03

Applicant: VERTEX PHARMA

Inventor： VERWIJS MARINUS JACOBUS ,  ALARGOVA ROSSITZA GUEORGUIEVA ,  KAUSHIK RITU ROHIT ,  KADIYALA IRINA NIKOLAEVNA ,  YOUNG CHRISTOPHER

IPC: A61K31/443 ,  A61K9/00 ,  A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61K9/28 ,  A61K31/47 ,  A61K45/06 ,  C07D405/12 ,  C07D405/14 ,  C07D451/02

Abstract: Una tableta para administración oral que comprende: a. 25 mg a 250 mg de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico (Compuesto 1) Forma I; b. un relleno; c. un disgregante; d. un surfactante; e. un lubricante y f. un aglutinante que es polivinilpirrolidona.

公开(公告)号：AU2013290444B2

公开(公告)日：2018-04-26

申请号：AU2013290444

申请日：2013-07-15

Applicant: VERTEX PHARMA

Inventor： ALARGOVA ROSSITZA GUEORGUIEVA ,  DUNBAR CRAIG ANTONY ,  KADIYALA IRINA NIKOLAEVNA

IPC: A61K9/20 ,  A61K31/404 ,  A61K31/47 ,  A61K45/06 ,  A61P43/00

Abstract: A pharmaceutical composition comprising Compound 1, (

公开(公告)号：NZ708598A

公开(公告)日：2017-05-26

申请号：NZ70859811

申请日：2011-04-07

Applicant: VERTEX PHARMA

Inventor： YOUNG CHRISTOPHER RYAN ,  KAUSHIK RITU ROHIT ,  ALARGOVA ROSSITZA GUEORGUIEVA ,  KADIYALA IRINA NIKOLAEVNA ,  VERWIJS MARINUS JACOBUS

IPC: A61K9/16 ,  A61K9/20 ,  A61K9/28 ,  C07D213/75 ,  C07D405/12 ,  C07D405/14

Abstract: Disclosed is a pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2- difluorobenzo[d][1,3]dioxol-5-y1)cyclopropanecarboxamido)-3-methylpyridin-2-y1)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis.

公开(公告)号：HK1209318A1

公开(公告)日：2016-04-01

申请号：HK15109966

申请日：2015-10-13

Applicant: VERTEX PHARMA

Inventor： ALARGOVA ROSSITZA GUEORGUIEVA ,  DUNBAR CRAIG ANTONY ,  KADIYALA IRINA NIKOLAEVNA

IPC: A61K20060101 ,  A61P20060101

公开(公告)号：AU2015202975A1

公开(公告)日：2015-06-18

申请号：AU2015202975

申请日：2015-06-03

Applicant: VERTEX PHARMA

Inventor： ALARGOVA ROSSITZA GUEORGUIEVA ,  DUNBAR CRAIG ANTONY ,  KADIYALA IRINA NIKOLAEVNA

IPC: A61K9/20 ,  A61K31/404

Abstract: PHARMACEUTICAL COMPOSITION OF (R)-1-(2,2 DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)-N-(1 -(2,3-DIHYDROXY PROPYL)-6-FLUORO-2-(1 -HYDROXY-2-METHYLPROPAN-2-YL)-1 H INDOL-5-YL) CYCLOPROPANECARBOXAMIDE AND ADMINISTRATION THEREOF A pharmaceutical composition comprising Compound , (R)-1-(2,2-difluorobenzo[d][1,3]dioxol 5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-IH-indol-5 yl)cyclopropanecarboxamide, and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering the pharmaceutical composition of Compound I are also disclosed.

公开(公告)号：AR084473A1

公开(公告)日：2013-05-22

申请号：ARP110103065

申请日：2011-08-23

Applicant: VERTEX PHARMA

Inventor： ALARGOVA ROSSITZA GUEORGUIEVA ,  DUNBAR CRAIG ANTONY ,  KADIYALA IRINA NIKOLAEVNA

IPC: A61K9/20 ,  A61K31/404

Abstract: Una composición farmacéutica que comprende el compuesto 1, (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-N-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1H-indol-5-il)ciclopropanecarboxamida, y al menos un excipiente seleccionado del grupo consistente en: un relleno, a diluyente, un desintegrante, un surfactante, un deslizante y un lubricante, siendo la composición adecuada para su administración oral a un paciente que la necesita para tratar una enfermedad mediada por CFTR tales como fibrosis quística. Se describen métodos para tratar un paciente que lo necesite, los cuales incluyen administrar la composición farmacéutica del compuesto 1.

公开(公告)号：AU2011237601A1

公开(公告)日：2012-11-01

申请号：AU2011237601

申请日：2011-04-07

Applicant: VERTEX PHARMA

Inventor： VERWIJS MARINUS JACOBUS ,  ALARGOVA ROSSITZA GUEORGUIEVA ,  KAUSHIK RITU ROHIT ,  KADIYALA IRINA NIKOLAEVNA ,  YOUNG CHRISTOPHER RYAN

IPC: A61K9/20

Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2- difluorobenzo [d] [ 1,3 ] dioxol-5 -y1) cyclopropanecarboxamido)-3 -methylpyridin-2-y1)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.